Basic Information
LncRNA/CircRNA Name | circU2AF1 |
Synonyms | circ_0061868 |
Region | |
Ensemble | |
Refseq |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | apoptosis | Drug | ||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | glioma |
ICD-0-3 | NA |
Methods | Apoptosis assay, Cell cycle assay, Migration and invasion assays, qRT??CR, Western blot, Dual luciferase activity assay, Biotin pull down assay, In vivo xenografting |
Sample | primary glioma tissue, glioma cell lines U87MG and U251 and the normal glial cell line HE |
Expression Pattern | up-regulated |
Function Description | the expression levels of circ-U2AF1 and NOVA2 were upregulated, while hsa-miR-7-5p was downregulated in human glioma tissues and glioma cell lines. Our data and bioinformatic analysis indicated the association of these molecules with glioma grade, a positive correlation between circ-U2AF1 and NOVA2 expression levels and a negative correlation of hsa-miR-7-5p with both circ-U2AF1 and NOVA2, respectively. In addition, silencing of circ-U2AF1 expression resulted in increased hsa-miR-7-5p expression and decreased NOVA2 expression both in vitro and in vivo. Luciferase assay confirmed hsa-miR-7-5p as a direct target of circ-U2AF1 and NOVA2 as a direct target of hsa-miR-7-5p. Functionally, silencing of circ-U2AF1 inhibits glioma development by repressing NOVA2 via upregulating hsa-miR-7-5p both in vitro and in vivo. |
Pubmed ID | 30341906 |
Year | 2018 |
Title | Circ??2AF1 promotes human glioma via derepressing neuro??ncological ventral antigen 2 by sponging hsa??iR????p |
External Links
Links for circU2AF1 | GenBank HGNC NONCODE |
Links for glioma | OMIM COSMIC |